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Leukemia inhibitory factor modulates the
peripheral immune response in a rat model
of emergent large vessel occlusion
Stephanie M. Davis1, Lisa A. Collier1, Edric D. Winford2, Christopher C. Leonardo5, Craig T. Ajmo Jr5,
Elspeth A. Foran6, Timothy J. Kopper3,4, John C. Gensel3,4 and Keith R. Pennypacker1,2*

Abstract
Background: The migration of peripheral immune cells and splenocytes to the ischemic brain is one of the major
causes of delayed neuroinflammation after permanent large vessel stroke. Other groups have demonstrated that
leukemia inhibitory factor (LIF), a cytokine that promotes neural cell survival through upregulation of antioxidant
enzymes, promotes an anti-inflammatory phenotype in several types of immune cells. The goal of this study was to
determine whether LIF treatment modulates the peripheral immune response after stroke.
Methods: Young male (3 month) Sprague-Dawley rats underwent sham surgery or permanent middle cerebral
artery occlusion (MCAO). Animals were administered LIF (125 μg/kg) or PBS at 6, 24, and 48 h prior to euthanization
at 72 h. Bone marrow-derived macrophages were treated with LIF (20 ng/ml) or PBS after stimulation with
interferon gamma + LPS. Western blot was used to measure protein levels of CD11b, IL-12, interferon inducible
protein-10, CD3, and the LIF receptor in spleen and brain tissue. ELISA was used to measure IL-10, IL-12, and
interferon gamma. Isolectin was used to label activated immune cells in brain tissue sections. Statistical analysis was
performed using one-way ANOVA and Student’s t test. A Kruskal-Wallis test followed by Bonferroni-corrected
Mann-Whitney tests was performed if data did not pass the D’Agostino-Pearson normality test.
Results: LIF-treated rats showed significantly lower levels of the LIF receptor and interferon gamma in the spleen
and CD11b levels in the brain compared to their PBS-treated counterparts. Fluorescence from isolectin-binding
immune cells was more prominent in the ipsilateral cortex and striatum after PBS treatment compared to LIF
treatment. MCAO + LIF significantly decreased splenic levels of CD11b and CD3 compared to sham surgery. MCAO
+ PBS treatment significantly elevated splenic levels of interferon inducible protein-10 at 72 h after MCAO, while LIF
treatment after MCAO returned interferon inducible protein 10 to sham levels. LIF administration with interferon
gamma + LPS significantly reduced the IL-12/IL-10 production ratio compared to macrophages treated with
interferon gamma + LPS alone.
Conclusions: These data demonstrate that LIF promotes anti-inflammatory signaling through alterations of the
IL-12/interferon gamma/interferon inducible protein 10 pathway.
Keywords: Stroke, Inflammation, Macrophages, Ischemia, Cytokines
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Background
Permanent occlusion of the brain’s major arteries, also
known as emergent large vessel occlusion (ELVO), is
one of the deadliest types of acute ischemic stroke and a
major cause of adult disability [1–3]. Due to the size of
the thrombus creating the blockage, ELVO patients are
often resistant to treatment with tissue plasminogen
activator (tPA), the only FDA-approved drug for the
treatment of stroke. The increased use of stent retrievers
for performing endovascular thrombectomy has allowed
for restoration of cerebral blood flow up to 24 h after
the onset of symptoms [4–6]. However, patients who are
deemed ineligible for endovascular thrombectomy are
left without sufficient treatment options [7]. Our laboratory has examined the inflammatory response to stroke
using the permanent middle cerebral artery occlusion,
which simulates ELVO.
Although neural cell death during large-vessel stroke
is commonly associated with energy failure and low
levels of oxygen, resulting brain damage occurs during
two distinct phases of cellular damage. The acute cytotoxicity phase, which occurs minutes to hours after the
onset of stroke, results in the death of cells within the ischemic core. The second phase of brain damage begins
approximately 12–24 h after the onset of focal cerebral ischemia and results from systemic activation of the peripheral immune system [8, 9]. Within the ischemic brain,
dying neurons and glia release compounds such as
ATP, fractalkine, or other danger-associated molecular patterns, which activate microglia, the resident macrophagelike immune cells in the brain [10–13]. Once activated,
microglia damage the blood-brain barrier via the release of pro-inflammatory cytokines and matrix metalloproteinases [14].
Increased permeability of the blood-brain barrier contributes to cerebral edema and renders cells in the parenchyma vulnerable to invading peripheral immune cells.
These immune cells infiltrate the brain approximately
48 h after cerebral ischemia and include monocytes/
macrophages, lymphocytes, and neutrophils [15–17].
Although certain populations of these immune cells,
such as anti-inflammatory macrophages/microglia, may
play a crucial role in phagocytosis and tissue repair,
pro-inflammatory leukocytes potentiate further damage
in the area surrounding the ischemic core (penumbra).
In addition, peripheral B and T cells that are exposed to
CNS-specific antigens may contribute towards the
post-stroke adaptive immune response by antibody secretion or direct cytotoxicity [18, 19]. This secondary
phase continues until approximately 96 h after the onset of stroke, when the infarct reaches its maximum
volume [20, 21].
Of the peripheral immune cell populations that migrate to the brain after stroke, a substantial portion of

Page 2 of 17

them originate in the spleen. After stroke, elevated levels of
norepinephrine and epinephrine mediate splenic contraction through the activation of α- and β-adrenoreceptors in
the white pulp, where splenic leukocytes reside [22, 23].
These leukocytes are released into the peripheral circulation, although the secretion of pro-inflammatory mediators
causes these cells to migrate towards the injured hemisphere and amplify the inflammatory response in the brain.
Previous studies revealed inverse relationships between
post-stroke spleen weights and infract volumes in addition
to spleen weights and splenic CD8+ cytotoxic T cell count.
These findings show that greater splenic atrophy is the
result of more infiltrating immune cells, which mediate
delayed neurodegeneration [24–27]. Our lab previously
demonstrated that splenectomy 2 weeks prior to permanent middle cerebral artery occlusion (MCAO) had
significantly increased infarct volumes after stroke [26].
Interferon gamma (IFNγ) production by T cells and
natural killer (NK) cells and subsequent induction of
interferon inducible protein 10 (IP-10) triggers the first
step in the delayed inflammatory response [26, 28–30].
Clinical data have shown that this post-stroke splenic
response not only occurs in human stroke patients, but
also differs among patients of different ages and racial
backgrounds [31–33].
Leukemia inhibitory factor (LIF) is a cytokine in the
IL-6 family that promotes survival of neurons and glia in
several animal models of neurodegenerative disease,
such as amyotrophic lateral sclerosis [34, 35], multiple
sclerosis [36–42], spinal cord injury [43, 44], and stroke
[45–47]. Our laboratory has identified several cytoprotective mechanisms of LIF, which include the upregulation of
antioxidant enzymes peroxiredoxin IV and metallothionein
III in oligodendrocytes [46, 48] and superoxide dismutase
3 in neurons [47]. Other groups have shown that in the efficacy of LIF in treating animal models of neurodegenerative disease may lie in its ability to modulate the immune
system in addition to its pro-survival signaling [42, 49].
Several groups have reported that LIF alters the phenotype of macrophages/microglia from a pro-inflammatory to
an anti-inflammatory phenotype. While pro-inflammatory
macrophages worsen tissue damage during stroke via the
release of pro-inflammatory mediators (tumor necrosis factor-α, IL-12, IL-6, IL-1β, nitric oxide, etc.),
anti-inflammatory cells are primarily phagocytic and
release anti-inflammatory mediators. In addition, these
macrophages/microglia recruit other anti-inflammatory
cells such as CD4 + CCR4+ helper T lymphocytes and
regulatory T cells (Tregs) to the site of injury. Duluc et al.
demonstrated that LIF and IL-6, in conjunction with
macrophage colony-stimulating factor cause monocytes to
differentiate into IL-12low IL-10high tumor-associated macrophages, a specialized class of anti-inflammatory leukocytes that protect cancerous growths from NK cells [50].
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Although pro-inflammatory macrophages/microglia further damage neural cells after stroke by perpetuating
inflammation and producing reactive oxygen species,
macrophages/microglia with an anti-inflammatory phenotype contribute to the repair process during ischemia
[13, 51]. Therefore, LIF may indirectly reduce the
neuroinflammation-associated damage during stroke
by increasing the population of anti-inflammatory
macrophages/microglia.
Previously, we showed that LIF reduces tissue damage
and improves function recovery after stroke through the
Akt-dependent upregulation of antioxidant enzymes in
neurons and oligodendrocytes [46, 47]. The purpose of this
study is to determine whether LIF alters the post-stroke
splenic response by changing the phenotype of macrophages/microglia from a pro-inflammatory to an
anti-inflammatory phenotype.

Methods
Animal care

Animal procedures were pre-approved by the Institutional
Animal Care and Use Committee at the University of
South Florida and performed according to the NIH Guide
for the Care and Use of Laboratory Animals. Power analysis was used to determine the appropriate number of
animals for each experiment. Sprague–Dawley rats were
purchased from Envigo (Indianapolis, IN, USA). C57BL/6
mice were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). Animals were maintained on a 12-h
light–dark cycle (07:00–19:00 h) in a climate-controlled
room and allowed access to food and water ad libitum. In
vivo procedures were performed on young (3 months),
male rats weighing between 300 and 350 g. For in vitro experiments, bone marrow was harvested from young mice
(2–3 months).

Middle cerebral artery occlusion

Permanent focal cerebral ischemia was induced using
the intraluminal middle cerebral artery occlusion
(MCAO) model as previously described [52]. A 40-mm
monofilament was introduced through the ligated external carotid artery and advanced through the internal
carotid artery. The filament was advanced until it
reached the origin of the middle cerebral artery.
Reduction in cerebral blood flow was confirmed using
Laser Doppler (Moore Lab Instruments, Farmington,
CT). Only animals experiencing ≥ 60% reduction in
cerebral perfusion were included in the study. Animals
subjected to the sham MCAO procedure were anesthetized and underwent exposure of the common carotid
artery without subsequent occlusion of the middle cerebral artery.
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Drug treatment

All animals were treated prophylactically with ketoprofen
(10 mg/kg s.c.), atropine (0.25 mg/kg s.c.) with two additional doses of ketoprofen at 24 and 48 h post-MCAO.
Recombinant human LIF (ProSpec, Ness Ziona, Israel)
(125 μg/kg) or PBS (pH 7.4) was administered intravenously at 6, 24, and 48 h post-MCAO as previously described [46, 47]. Animals were randomly assigned to
treatment groups and all lab personnel administering
drugs were blinded to treatments.
Tissue collection

Rats were euthanized at 72 h post-MCAO via intraperitoneal injection of ketamine/xylazine solution (75 mg/kg
and 7.5 mg/kg) [53]. Spleens were collected immediately
prior to perfusion. Animals used for immunohistochemical analysis were perfused transcardially with normal
saline followed by 4% paraformaldehyde in phosphate
buffer. Animals used for biochemical analysis were perfused with saline but not paraformaldehyde prior to
obtaining tissue. Fresh brain tissue was separated into ipsilateral and contralateral hemispheres, snap-frozen, and
stored at − 80 °C until further processing. Fixed brains
were cryopreserved in 20% followed by 30% sucrose solutions and cut into 30-μm sections using a cryostat. Brain
tissue used in these experiments was located between + 1.7
and − 3.3 mm from the bregma.
Tissue homogenization

To obtain whole cell extracts, frozen tissue was homogenized in whole cell lysis buffer containing the following:
50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% IGEP
AL, 1 mM PMSF, and a Complete Mini protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). An
electric homogenizer was used to disrupt tissue, and lysates were incubated on ice for 20 min. Tissue lysates
were vortexed and pipetted to break up nuclei. Protein
concentrations were determined by performing a Bradford Assay according to the manufacturer’s protocol
(Bio-Rad, Hercules, CA). Briefly, Bradford reagent containing Coomassie blue was added to diluted protein
samples and absorbance was read at 595 nm using a
SmartSpec 3000 spectrophotometer (Bio-Rad). Concentrations were determined by comparing the absorbance
readings against a standard curve.
Isolectin staining

Isolectin IB4 (0.05% v/v) from Griffonia simplicifolia conjugated to AlexaFluor® 488 dye was used to label activated
macrophages and microglia in the cortical and striatal tissue of PBS- and LIF-treated rat brains according to a
previously described procedure [20]. Coverslips were
mounted onto slides using VECTASHIELD® medium containing 4′, 6-diamidino-2-phenylindole (DAPI) (Vector
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Labs, Burlingame, CA). Images were captured using a
Nikon Eclipse Ti microscope (Minato, Tokyo, Japan) interfaced with NIS Elements Imaging Software (Nikon).
3,3-Diaminobenzidine immunohistochemistry

To detect CD11b-positive cells in brain tissue, 3,3-diaminobenzidine (DAB) immunohistochemistry was performed according to a previously described protocol
[54]. The following antibodies were used: mouse
α-CD11b (OX42) (1:3000; Bio-Rad; Hercules, CA) and
horse α-mouse (1:300; Vector-Labs; Berlingame, CA).
Slides were cover slipped with DPX medium (BDH Laboratories, Poole, England) and images were acquired
with a Nikon Eclipse Ti microscope interfaced with NIS
Elements Imaging Software (Nikon).
DAB staining of spleen tissue was also performed according to a previously described protocol, albeit with
minor modifications. Briefly, cryopreserved spleen tissue
sections (30 μm) were dried at 37 °C, rehydrated with
PBS (pH 7.4), and permeabilized for 1 h containing 10%
goat serum, 0.3% 1 M Lysine, and 0.3% Triton-X-100.
Following permeabilization, spleen sections were treated
for 40 min with 3% H2O2 to quench endogenous peroxidase activity. Sections were incubated overnight in the
following antibodies: rabbit α-LIFR (1:200; Santa Cruz;
RRID:AB_2136015) and mouse α-FoxP3 (1:5000; Abcam;
RRID:AB_447114). Secondary detection was achieved
using goat α-rabbit and goat α-mouse biotinylated secondary antibodies (1:300; Vector Labs). Slides were mounted
with DPX medium (BDH Laboratories) after dehydration
with ethanol and clearing with xylenes. All images were
acquired using a Nikon Eclipse Ti microscope interfaced
with NIS Elements Imaging Software (Nikon).
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Bone marrow-derived macrophage cell culture

Bone marrow-derived macrophages (BMDMs) were isolated from C57BL/6 mice (3 months of age) as previously
described [55–57]. Briefly, cells were extracted from the
femur and tibia and seeded at a density of 8 × 105–1 × 106
cells/ml in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% FBS, 1% penicillin/streptomycin, 1%
HEPES, 0.001% β-mercaptoethanol, and 20% supernatant containing macrophage colony-stimulating factor
from SL929 cells (gifted by Phillip Popovich from The
Ohio State University) [58]. Following 7 days of in vitro
differentiation, cells were re-seeded at a density of 1 × 106
cells/ml in DMEM containing 10% FBS, 1% penicillin/
streptomycin, 1% HEPES, and 0.001% β-mercaptoethanol.
The next day, a classically activated phenotype (M1)
was induced using N2A medium containing LPS
(50 ng/ml) and IFNγ (20 ng/ml). LIF (20 ng/ml) or PBS
was co-administered with the LPS and IFNγ. Macrophageconditioned media was collected 24 h after stimulation and
centrifuged at 13,000 rpm at 4 °C for 10 min prior to measurement of IL-12 p40 and IL-10 via ELISA [59].

ELISA

To measure the release of IFNγ, TNFα, IL-1β, IL-6, and
IL-10 in rat spleen tissue, ELISA was performed according to manufacturer’s protocol using the appropriate
DuoSet ELISA kits (R&D Systems, Inc., Minneapolis,
MN). ELISA was also used to measure IL-12 p40 and
IL-10 release in macrophage supernatants according to
the manufacturer’s protocol using the Mouse IL-12 p40
and IL-10 ELISA kits (Cat # EMIL12P40 and Cat #
EM2IL105; Thermo Fisher Scientific, Waltham, MA).

Western blot analysis

Data analysis

Western blotting was used for semi-quantitative measurement of protein expression using a previously described
procedure [47]. Briefly, whole cell lysates from brain and
spleen tissue were run on 10% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were
blocked in Li-Cor TBS-based Blocking Buffer (Lincoln,
NE) and probed with the following antibodies: rabbit
α-LIFR (1:100; Santa Cruz), rabbit α-IL-12 p40 (1:100;
Abbiotec RRID:AB_10636335), mouse α-CD11b (1:1000;
Abcam). Membranes were incubated in IRDye 800CW
goat α-rabbit antibodies (1:20,000; Li-Cor; RRID:AB_2651127) for detection of protein bands. Membranes were visualized using the Odyssey CLx Imaging
System (Li-Cor). To normalize for loading, membranes
containing whole cell extracts were re-probed with mouse
α-β-actin (1:5000; Novus Biologicals; RRID:AB_1216153)
and IRDye 680RD goat α-mouse antibodies (1:20,000;
Li-Cor; RRID:AB_10956588).

Images were minimally processed in a uniform matter
across treatment groups and were analyzed using ImageJ
software (NIH, Bethesda, MD). The D’Agostino-Pearson
test was performed to determine whether data was normally distributed. Statistical analysis for experiments
containing two groups was performed using Student’s t
test, or the Mann-Whitney U Test if the data sets did not
pass the D’Agostino-Pearson test. Welch’s correction was
used in the case of unequal variances. Statistical analysis
for experiments containing three or more groups was performed using the one-way ANOVA followed by Fisher’s
Protected LSD test to determine individual differences
If data did not pass the D’Agostino-Pearson test, the
Kruskal-Wallis H test was used, and individual differences were detected using Bonferroni-corrected MannWhitney U tests. A p value equal to 0.05 or less was
considered statistically significant. All reported p values
are one-tailed.
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Results
LIF decreases LIFR expression but does not alter spleen
weight after MCAO

Western blotting was used to determine whether MCAO
and LIF treatment altered levels of LIFR in the spleen at
72 h post-MCAO. At 72 h post-MCAO, there was a significant change in splenic LIFR expression among sham,
PBS, and LIF-treated rats (F2,21 = 3.511; p = 0.0484). LIFR
levels in the spleens of LIF-treated (p = 0.0086) but not
PBS-treated rats were significantly lower than those of
sham rats (Fig. 1a). When the levels of LIFR were
normalized to the weight of each spleen, there was no
significant difference in normalized splenic LIFR levels
between sham-operated, PBS-treated, and LIF-treated
rats (H = 4.295; p = 0.1168). However, there was a trend
towards increased normalized LIFR levels in PBS-treated
rats compared to the other treatment groups (Fig. 1b).
Compared to spleens from sham-operated rats, MCAO
and LIF treatment caused a significant overall change in
the average spleen weight (p = 0.0008, F2,56 = 8.143).
There was a significant decrease in spleen weight among
rats treated with PBS after MCAO compared to the
sham-operated rats (p = 0.0001). Rats treated with LIF
after MCAO had significantly smaller spleen weights
compared to sham-operated rats (p = 0.0062). There was
a trend towards larger spleens among rats treated with
LIF post-MCAO compared to the PBS-treated group,
but this trend was not significant (p = 0.1016; Fig. 1c).
Splenocytes express the LIF receptor after MCAO and LIF
treatment

Spleen tissue sections were stained with antibodies
against LIFR in order to visualize the LIF receptor in
splenocytes after sham surgery, MCAO + PBS treatment,
and MCAO + LIF treatment. Punctate LIFR immunoreactivity was observed in spleens from sham-operated
rats while spleens from the MCAO + PBS and MCAO +
LIF groups showed more diffuse staining in splenocytes.
Arrows are used to identify representative cells (Fig. 2).
Splenic CD11b expression decreases after MCAO and LIF
treatment

Western blotting was used to measure CD11b protein
expression in the spleens of PBS and LIF-treated rats
euthanized at 72 h after MCAO. At 72 h, levels of
CD11b in spleen tissue were significantly altered after
MCAO and LIF treatment (p = 0.0003; F2,21 = 12.51).
There was a significant drop in CD11b levels in the
spleens of PBS-treated rats (p = 0.002) and LIF-treated
(p = 0.0002) rats compared to those of sham rats
(Fig. 3a). When the CD11b levels were normalized to
the spleen weights of each sample, there was a significant
overall change in normalized CD11b levels (p = 0.0335;
F2,21 = 4.009) and a significant decrease in normalized

Fig. 1 LIF treatment decreases splenic LIFR but does not change
spleen weight. a Western blotting was used to measure levels of the
LIF receptor (LIFR) in the spleen 72 h after sham surgery and MCAO.
There was a trend towards decreased LIFR levels after MCAO and a
significant decrease in LIFR after MCAO and treatment with LIF
(**p < 0.01). n = 8 animals per treatment group. b When LIFR protein
levels were normalized to the spleen weight, there was a trend
towards increased normalized LIFR in the PBS-treated group, but this
increase was not significant. c At 72 h, spleen weights in the MCAO
+ PBS group (****p < 0.0001) and the MCAO + LIF (**p < 0.01) were
significantly lower than the sham group. There was a trend towards
a higher spleen weight in the MCAO + LIF group compared to the
MCAO + PBS group, but this trend was not significant (p = 0.1016).
n = 18–23 animals per treatment group
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Fig. 2 LIFR+ splenocytes are observed in the spleen after MCAO and LIF treatment. DAB immunohistochemistry was used to visualize the
expression of LIFR among splenocytes in tissue from sham-operated, PBS-treated, and LIF-treated cells. Although LIFR+ splenocytes were found in
all three treatment groups, LIFR+ positive cells showed punctate immunoreactivity while tissue from PBS- and LIF-treated animals showed more
diffuse immunoreactivity. Arrows identify representative cells. Scale bar = 50 μm

CD11b after MCAO + LIF treatment compared to sham
levels (p = 0.0043; Fig. 3b). To determine the relationship
between spleen weight and levels of CD11b in splenic
tissue, Pearson r correlation analysis was performed.
There was a significant positive correlation between the
spleen weight at 72 h post-MCAO and sham procedure
and splenic CD11b protein expression (p = 0.0149;
Pearson r = 0.4437; Fig. 3c).
IL-12 p40 levels in the spleen are not altered after MCAO
and LIF treatment

To measure release of IL-12 after MCAO and LIF treatment, western blotting was used to detect levels of IL-12
p40 in splenic tissue. There was no overall significant alteration in IL-12 p40 protein levels at 72 h after MCAO
and LIF treatment (p = 0.098; F2,21 = 2.600). However,
there was a strong trend towards decreased IL-12 p40
levels in the spleens of LIF-treated rats compared to
PBS-treated and sham rats (Fig. 4a). When splenic IL-12
p40 levels were normalized to spleen weights, there was a
trend towards increased normalized IL-12 p40 levels in
the spleens of PBS-treated rats compared to LIF-treated
and sham-operated rats (F2,21 = 2.721, p = 0.0890; Fig. 4b).
TNFα, but not IL-6 and IL-1b, are altered by MCAO + LIF
treatment at 72 h after MCAO

ELISA was used to measure levels of TNFα in the spleen
tissue of sham, PBS-treated, and LIF-treated rats at 72 h
after MCAO. There was a significant alteration in TNFα
levels at this time point (F2,21 = 6.181; p = 0.0077. TNFα
levels were significantly lower after MCAO compared to
sham levels (p = 0.0347) and after MCAO + LIF treatment
compared to sham levels (p = 0.0012). However, there was
no significant difference between the mean TNFα levels in
the MCAO + PBS and MCAO + LIF groups (p = 0.1038;
Fig. 5a). ELISA was also used to measure levels IL-1β and
IL-6 in spleen tissue. There was a trend towards decreased IL-1β (F2,20 = 3.157; p = 0.0644; Fig. 5b) and

IL-6 (F2,13 = 0.3225; p = 0.7300; Fig. 5c) levels after
MCAO + LIF treatment but this difference was not
statistically significant.
Splenic IL-10 is not altered by MCAO + LIF treatment

Levels of IL-10 were measured in spleen tissue at 72 h
post-MCAO using ELISA. Although there was a trend
towards decreased IL-10 levels in the MCAO + PBS and
MCAO + LIF groups that approached significance
(F2,20 = 3.437; p = 0.0521), the overall difference was
not statistically significant (Fig. 6).
LIF reduces CD3 immunoreactivity in the spleen

To determine whether LIF decreases development of
mature T cells, western blotting was used to measure
levels of CD3, a pan-T cell marker, in spleen tissue
at 72 h after MCAO. At 72 h, there was a significant
change in CD3 levels between spleen tissue from
sham-operated, PBS-treated, and LIF-treated young
rats (F2,20 = 5.198, p = 0.0152). There were significant
decreases in overall CD3 levels in the spleens of
PBS-treated (p = 0.0405) and LIF-treated rats compared to
sham-operated rats (p = 0.0113; Fig. 7a). When CD3 levels
were normalized to spleen weight, there was no significant
difference in normalized CD3 between the three treatment
groups (F2,20 = 2.434; p = 0.1132; Fig. 7b).
FoxP3+ immunoreactivity is observed in the spleen after
MCAO + LIF treatment

Spleen sections from sham-operated, PBS-treated, and
LIF-treated rats were stained with FoxP3 antibodies to
identify the presence of Tregs. FoxP3+ cells were found
in representative spleen sections from all three treatment groups, although FoxP3 immunoreactivity was
more prominent in the representative sections from the
MCAO + PBS and MCAO + LIF groups (Fig. 8).
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Fig. 4 LIF does not alter splenic IL-12 p40 levels after MCAO.
Western blotting was used to measure levels of the IL-12 p40
subunit in the spleen 72 h after sham surgery and MCAO. a There
was no significant overall change in IL-12 p40 levels after MCAO and
LIF treatment, but there was a trend towards decreased IL-12 p40
levels in the MCAO + LIF group compared to the sham and MCAO +
PBS groups that approached significance. b When IL-12 p40 levels
were normalized to spleen weights, there was a trend towards
increased IL-12 p40 in the MCAO + PBS group compared to the MCAO
+ LIF and sham groups. n = 8 animals per treatment group
Fig. 3 Splenic CD11b levels are significantly decreased after MCAO
and LIF treatment. a Western blotting was used to measure levels of
CD11b, a marker of activated macrophages/microglia, in the spleen
72 h after sham surgery and MCAO. Levels of CD11B were
significantly lower in the MCAO + PBS group (**p < 0.01) and the
MCAO + LIF (***p < 0.001) were significantly lower than the sham
group. b When CD11b levels were normalized to spleen weight,
there was a significant decrease in normalized CD11b after LIF
treatment compared to sham levels (**p < 0.01). c According to the
results of the Pearson correlation analysis, there was a significant
correlation between spleen weights and CD11b levels in the spleen
(*p < 0.05). n = 8 animals per treatment group

IFNγ release is decreased by MCAO and LIF treatment

IFNγ levels in spleen tissue from sham, PBS-treated, and
LIF-treated rats was measured using an ELISA kit and
normalized to the total protein. There was a significant change in IFNγ levels in the spleen tissue of
sham-operated, PBS-treated, and LIF-treated rats at
72 h post-MCAO (F2,21 6.365; p = 0.0069). There was a
significant decrease in IFNγ levels in the spleens of the
MCAO + PBS group (p = 0.0364) and the MCAO + LIF
group (p = 0.0095) compared to the sham levels. In
addition, spleen tissue from the MCAO + LIF group had
significantly lower IFNγ levels compared to tissue from
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Fig. 6 IL-10 levels are not altered by MCAO and LIF treatment. ELISA
was used to measure IL-10 in spleen tissue samples. Although there
was a trend towards decreased IL-10 after MCAO (regardless of PBS
or LIF treatment), the change was not quite statistically significant
overall. n = 7–8 animals per treatment group

LIF treatment counteracts the increase in splenic IP-10
after MCAO

Fig. 5 MCAO + LIF treatment alters splenic TNFα, but not IL-1β and
IL-6. ELISA was used to measure levels of TNFα, IL-1β, and IL-6 in
spleen tissue at 72 h after MCAO. a There was a significant decrease
in TNFα levels after MCAO + PBS treatment (*p < 0.05) and MCAO +
LIF treatment (**p < 0.01) compared to sham levels. However, there
was no significant overall change in b IL-1β levels or c IL-6 levels
between treatment groups. n = 4–7 animals per treatment group

the MCAO + PBS rats (p = 0.0324; Fig. 9a). Normalizing IFNγ levels in each sample to the spleen weight
also showed a significant alteration in normalized
splenic IFNγ after MCAO and LIF treatment (F2,21 =
5.052, p = 0.0162). MCAO + PBS treatment significantly increased normalized IFNγ compared to sham
levels (p = 0.0038), but LIF treatment significantly
reduced normalized IFNγ levels compared to PBS
treatment (p = 0.0080; Fig. 9b).

IP-10 levels were measured in splenic tissue using western
blotting. At 72 h after MCAO, there was a significant alteration in IP-10 protein expression in spleen tissue (H = 7.215;
p = 0.0271). Splenic IP-10 levels were significantly elevated
after MCAO compared to sham levels (p = 0.0045). The
levels of IP-10 in the spleens of LIF-treated rats were
not significantly different from sham levels (p = 1.000),
but there was a non-significant decrease in IP-10 expression compared to IP-10 expression levels of
PBS-treated rats (p = 0.1572; Fig. 10a). When the levels
of IP-10 in each tissue sample were normalized to the
spleen mass, there was a significant change in normalized
IP-10 levels at 72 h post-MCAO (H = 9.065; p = 0.0108).
Normalized IP-10 levels remained significantly elevated
compared to the sham group (p = 0.0015). However,
treatment with LIF counteracted this upregulation of
IP-10 compared to sham-operated animals (Fig. 10b).
LIF promotes anti-inflammatory phenotype in LPS/IFNγstimulated macrophages

Prior to stimulation with LPS + IFNγ to induce an M1
phenotype, BMDMs were treated with LIF (20 ng/ml) or
PBS. Levels of IL-12 p40 and IL-10 in the supernatant
were measured via ELISA. Unstimulated cells treated
with LIF or PBS were used as a control. After 24 h, M1
macrophages stimulated with LIF had released significantly less IL-12 p40 compared to M1 cells treated with
PBS (t = 6.530, df = 4, p = 0.0014; Fig. 11a). M1 BMDMs
showed significantly elevated release of IL-10 compared to
their unstimulated counterparts. Treatment with LIF prior
to stimulation further elevated IL-10 release among M1
cells (t = 2.942, df = 4, p = 0.0212; Fig. 11b). LIF treatment
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lectin-binding cells in the striatum after LIF treatment
displayed a more ramified phenotype. By contrast,
lectin-binding cells in the striatum displayed an
amoeboid phenotype after PBS treatment (Fig. 12a).
Antibodies against CD11b were also used to label
brain sections from animals treated with PBS or LIF
after MCAO. Representative images show a number of
amoeboid CD11b + cells in the cortex and striatum of
tissue from animals treated with PBS after MCAO. By
contrast, the cortical and striatal tissue from LIF-treated
rats contained more CD11b + cells with a ramified
phenotype (Fig. 12b).
Western blotting was used to quantify protein levels of
CD11b in homogenized brain tissue at 72 h after
MCAO. Levels of CD11b in the ipsilateral tissue of PBSand LIF-treated rats were normalized to the average
CD11b levels in sham brains. There was a significant
change in CD11b levels in the brain after MCAO and
LIF treatment (F3,18 = 7.800; p = 0.0015). CD11b levels
were significantly decreased in the ipsilateral hemisphere
of LIF-treated rats compared to those of PBS-treated
rats at 72 h after MCAO (p = 0.0432). Likewise, CD11b
levels were significantly higher in the ipsilateral hemisphere of LIF-treated rats (p = 0.0301) and PBS-treated
rats (p = 0.0037) compared to their contralateral counterparts (Fig. 12c).

Fig. 7 LIF decreases CD3 levels in the spleen after MCAO. Western
blotting was used to measure levels of CD3, a pan-T cell marker, in
spleen tissue. a At 72 h after sham surgery or MCAO, there was a
significant decrease in CD3 levels between sham-operated rats and
the PBS and LIF treatment groups (*p < 0.05). b However, there was
no significant change in CD3 expression when protein levels were
normalized to spleen weights. n = 7–8 animals per treatment group

also significantly decreased the ratio of IL-12 p40 release
to IL-10 release in the media compared to treatment with
PBS (t = 6.012, df = 4, p = 0.0019; Fig. 11c).
Activated macrophages/microglia are decreased in the
brains of LIF-treated rats

Activated macrophages/microglia were visualized in
fixed brain tissue from PBS- or LIF-treated rats using
isolectin-conjugated to AlexaFluor® 488 dye. At 72 h
after MCAO, there was a less isolectin-tagged fluorescence within the cortical and striatal tissue of
LIF-treated rats compared to their PBS-treated counterparts. Furthermore, representative images show that

Discussion
Although LIF treatment decreased protein levels of
CD11b as well as the numbers of isolectin-binding cells,
these results indicate that LIF exerts its primary immunomodulatory effects on splenocytes, specifically
through the IL-12 p40 /IFNγ/IP-10 axis. Offner et al.
previously demonstrated that induction of focal cerebral
ischemia in mice stimulates the production of several
pro-inflammatory cytokines from splenocytes [60]. This
upregulation of cytokine production is followed by a
time-dependent decrease in spleen weight due to the migration of splenocyte populations to the ischemic brain
[18, 23, 26, 27].
In accordance with previously published studies,
spleen size significantly decreased after MCAO compared to sham treatment, LIF-treated rats had a trend
towards a larger spleen size at 72 h after MCAO. Furthermore, there was a significant downregulation in
splenic LIFR protein expression in the spleens of
LIF-treated rats. LIFR is degraded after prolonged stimulation with LIF in many cell types, which indicates that
the splenocytes were responsive to peripherally administered LIF after stroke [61]. Although this laboratory has
previously shown that the decrease in spleen size is observed as early as 24 h after stroke, this laboratory did
not observe any LIF-mediated alteration in LIFR expression or spleen size prior to the 72-h time point [27].

Davis et al. Journal of Neuroinflammation (2018) 15:288

Page 10 of 17

Fig. 8 FoxP3+ cells are observed in the spleen after MCAO and LIF treatment. Antibodies against FoxP3 were used to label Tregs in
representative spleen tissue sections. Although FoxP3+ cells were found in representative tissue of sham-operated animals, there was noticeably
more immunoreactivity for FoxP3 in spleens of MCAO + PBS and MCAO + LIF animals. Arrows identify representative cells. Scale bar = 50 μm

However, published manuscripts from this group have
also shown that most prominent effects of LIF are observed at 72 h after MCAO, including improvement in
motor skills, decreased tissue damage, and upregulation
of antioxidant enzymes [46, 47]. Therefore, it should be
expected that the prominent anti-inflammatory effects
of LIF are observed at this time point.
Although this study primarily examined the effects of
LIF in the spleen and brain after stroke, it is entirely
possible that LIF signaling is indirectly modulating the
post-stroke immune response through its actions in
other tissues. Ajmo et al. previously demonstrated that
the activation of adrenoreceptors in the spleen is responsible for the splenic contraction that promotes the migration of immune cells to the brain after stroke [23].
Due to its effects on the hypothalamus-pituitary-adrenal
axis [62], it is possible that LIF administration is influencing the post-stroke immune response through the regulation of cortisol release [62, 63]. Furthermore,
leukocytes within the peripheral circulation, including T
cells, are responsible for perpetuating inflammation in
rodent models of ischemic stroke [60]. Therefore, it is
highly likely that systemically administered LIF is also
acting on immune cells within the peripheral blood in
addition to the spleen.
IL-12 is a heterodimer consisting of two subunits: the
35-kDa p35 subunit and the 40-kDa p40 submit, which is
a component of the pro-inflammatory cytokine IL-23.
Microglia and perivascular macrophages in brain produce
IL-12/IL-23 in response to stimulation with other
pro-inflammatory cytokines or damage-associated molecular patterns [19]. IL-12 p40 release from macrophages/microglia promotes further production of IL-12/
IL-23 by microglia/ macrophages and perivascular dendritic cells. After the breakdown of the blood-brain barrier
due to matrix metalloproteinase and cytokine production
by microglia, IL-12 p40-stimulated CD8+ cytotoxic T cells,
CD4+ type 1 helper T (Th1) cells, and NK cells release

IFNγ [64–66]. The results of the in vitro experiments with
BMDMs demonstrate that LIF directly reduces IL-12 p40
release from pro-inflammatory macrophages. Furthermore, LIF treatment promotes in vitro release of IL-10 in
BMDMs, an anti-inflammatory cytokine that counteracts
IL-12 p40-mediated production of IFNγ [67].
While this upregulation of IL-10 was not observed in
spleen tissue, it is possible that the migration of monocytes/macrophages into the peripheral circulation prior
to 72 h after MCAO prevents us from detecting any significant change in IL-12 p40 or IL-10 in the spleen at
this time point [20]. LIF treatment also did not significantly alter levels of IL-1β or IL-6, which are released
primarily by monocytes/macrophages [68, 69], at this
time point. However, IFNγ was significantly reduced in
the spleen after LIF treatment, which demonstrates that
LIF is primarily influencing the pro-inflammatory signaling generated by splenic T cells [27, 30, 53].
Our lab has demonstrated an essential role for T and
NK cell-derived IFNγ in the initiation of the post-stroke
splenic response. According to Seifert et al., splenic T
cells upregulate IFNγ at 24 h post-MCAO. Increased
IFNγ immunoreactivity in the ipsilateral hemisphere at
72 h post-MCAO corresponds with the infiltration of
splenic leukocytes. A splenectomy performed 2 weeks
prior to stroke onset or the administration of antibodies
to neutralize IFNγ significantly reduced neurodegeneration at 96 h post-MCAO. However, administration of exogenous IFNγ restored the neuroinflammatory response
in animals that underwent splenectomy [30, 53]. Following release by NK cells and T cells, IFNγ induces the
production of several chemokines in macrophages/
microglia, including monocyte induced by IFNγ,
interferon-inducible T cell α-chemoattractant, and IP-10
[70]. Western blot analysis showed that LIF treatment
significantly reduces levels of CD3, a marker for T cells,
in the spleen at 72 h post-MCAO. Although CD3 is
expressed by all T cells, this reduction coupled with the
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Fig. 9 IFNγ release in the spleen decreases after MCAO and LIF
treatment. IFNγ release in spleen tissue was measured using an
ELISA kit and normalized to the total protein concentration. a At
72 h after MCAO or sham surgery, there was a significant decrease
in IFNγ release after MCAO + PBS treatment (*p < 0.05) and MCAO +
LIF treatment (**p < 0.01) compared to sham levels. There was also a
significant decrease in IFNγ release after MCAO + LIF treatment
compared to the MCAO + PBS group (*p < 0.05). b When IFNγ levels
were normalized to spleen weights, normalized IFNγ was
significantly higher in the MCAO + PBS group compared to the
sham or MCAO + LIF groups. n = 8 animals per treatment group

downregulation in IFNγ production suggest that LIF prevents the maturation of CD8+ cytotoxic T cells, which are
the major producer of IFNγ after stroke [71, 72].
FoxP3-labeled spleen tissue from PBS-treated rats did not
show a notable difference in immunoreactivity between
PBS- and LIF-treated animals. While these results do not
rule out a possible effect on CD4 + CD25 + FoxP3+ Tregs,
the anti-inflammatory properties of LIF are more likely
due to its abilities to suppress IFNγ production by CD8+
and CD4+ Th1 cells.
IP-10 is a chemokine that facilitates chemotaxis of
pro-inflammatory CD4+ T cells to the ischemic brain via
binding to CXCR3 [73]. Alternatively, IP-10, along with

Page 11 of 17

Fig. 10 LIF Prevents the upregulation of splenic IP-10 levels at 72 h
after MCAO. IP-10 protein levels were measured in spleen tissue using
western blot. a There was a significant increase in IP-10 levels in the
spleens of the MCAO + PBS group compared to the sham group
(**p < 0.01). However, levels of IP-10 in the spleens of LIF-treated rats
were not significantly different from those in sham levels. Furthermore,
there was a trend towards decreased IP-10 levels in spleens of the
LIF-treated rats compared to those of the PBS-treated rats. b This same
pattern of expression was also seen when IP-10 levels were normalized
to spleen weights (**p < 0.01). n = 8 animals per treatment group

other IFNγ-inducible chemokines, promotes post-stroke
inflammation via antagonism of the binds to the CCR3
receptor on anti-inflammatory CD4+ T cells [74]. Offner
et al. first reported that IP-10 mRNA levels were increased at 22 h after transient MCAO in mice, and Seifert et al. confirmed that the IFNγ/IP-10 axis drives the
migration of T cells to the brain after stroke [18, 30, 75].
In this study, splenic IP-10 levels increased after MCAO
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Fig. 11 LIF treatment decreases IL-12 p40 release and increases
IL-10 release in pro-inflammatory BMDMs. A pro-inflammatory
(M1) phenotype was induced in BMDMs via stimulation with
IFNγ and LPS. LIF or PBS were co-administered with stimulants.
a At 24 h after stimulation, macrophage-conditioned media from
M1 cells treated with LIF had significantly lower IL-12 p40
release compared to media from M1 cells treated with PBS
(**p < 0.01). b IL-10 release in macrophage-conditioned media
from M1 cells treated with LIF compared to M1 cells treated
with PBS (*p < 0.05). c The average ratio of IL-12 p40/IL-10 in the
macrophage-conditioned media from LIF-treated M1 cells was
significantly lower than the IL-12 p40/IL-10 ratio in the PBStreated M1 cells (**p < 0.01). n = 3 wells per treatment group
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in PBS-treated rats compared to sham-operated rats, but
LIF treatment prevented the upregulation of IP-10 after
MCAO. By counteracting the IFNγ-mediated increase in
splenic IP-10, LIF treatment would decrease the number
of pro-inflammatory immune cells migrating to the
brain after stroke (Fig. 13).
Although most of the anti-inflammatory signaling promoted by LIF is occurring in the spleen, the decreased
isolectin-tagged fluorescence and normalized CD11b
levels in brain tissue demonstrate that LIF either decreases infiltration of monocytes/macrophages into the
ischemic hemisphere or attenuates the activation of
microglial cells after stroke [76]. According to Leonardo
et al., the increase lectin-tagged fluorescence after permanent MCAO corresponds with increased numbers of
CD11b + monocytes/macrophages into the penumbra
[20]. However, we also observed that CD11b + cells in
the cortical and striatal tissue of LIF-treated rats had
more of a ramified phenotype, while the amoeboid
phenotype was more prevalent in the tissue from
PBS-treated rats. Therefore, it is possible that LIF treatment influences microglial activation in addition to
monocytes/macrophages derived from the spleen. Since
IP-10 is primarily responsible for facilitating chemotaxis
of immune cells towards the ischemic brain, the decrease in the number of isolectin-tagged cells and
CD11b levels could correspond to a smaller population
of immune cells leaving the spleen [30, 77]. This explanation is further justified by the trend towards an increase
in spleen weight observed after LIF treatment.
Previously released publications from our laboratory
and other independent groups demonstrated that LIF
promotes tissue repair and functional recovery after
MCAO through Akt-dependent upregulation of protective antioxidant enzymes in neurons and oligodendrocytes. However, evidence suggests that certain
Akt-inducing biological therapeutics prevent the infiltration of monocytes/macrophages and lymphocytes into
the ischemic brain in addition to promoting
anti-oxidation. Rowe et al. showed that administration of
human umbilical cord blood (HUCB) cells at 48 h after
MCAO promotes oligodendrocyte survival via the upregulation of peroxiredoxin IV and metallothionein III.
In a later study by Shahaduzzaman et al., HUCB treatment after MCAO increased peroxiredoxin V expression
in neurons through increased Akt signaling [78]. However, soluble factors released from HUCB cells, which include LIF, also promote anti-inflammatory signaling
after stroke [46, 79]. Vendrame et al. demonstrated that
intravenously injected HUCB cells migrated to the
spleen during MCAO and partially counteracted the
splenic immune response after stroke. Splenocytes isolated from rats treated with human umbilical cord blood
cells after MCAO showed significantly decreased
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Fig. 12 LIF reduces isolectin-tagged fluorescence and CD11b levels in ischemic brain tissue. a Ipsilateral tissue sections from the MCAO + LIF
treatment group showed less isolectin-tagged fluorescence in the cortex and striatum than tissue from the MCAO + PBS treatment group.
Furthermore, isolectin-tagged cells in the striatum displayed a ramified phenotype, while isolectin-tagged cells in the striatum showed an
amoeboid phenotype after MCAO + PBS treatment. Arrows indicate representative cells. Scale bar = 100 μm. b CD11b antibodies were also used
to label cells in the cortical and striatal brain tissue from representative animals. While more amoeboid CD11b + cells were found in the cortex
and striatum of brains from representative PBS-treated animals, the CD11b + cells in the brains of LIF-treated animals showed a more ramified
phenotype. Scale bar = 50 μm. c Western blotting was performed to show levels of CD11b in the ipsilateral and contralateral brain tissue in PBS
and LIF-treated rats. There was a significant decrease in the ipsilateral CD11b levels after LIF treatment compared to PBS treatment (*p < 0.05).
CD11b levels were significantly elevated in the ipsilateral hemispheres of the PBS-treated (**p < 0.01) and LIF-treated (*p < 0.05) animals compared
to their contralateral counterparts. n = 5–6 animals per treatment group

production
of
IFNγ
after
stimulation
with
concavalin-A [80]. In a subsequent study, human umbilical cord blood cell treatment after MCAO significantly attenuated the migration of pro-inflammatory
isolectin-binding monocytes/macrophages into the ischemic brain [20]. Since the PI3K/Akt signaling axis
promotes an anti-inflammatory phenotype in microglia/macrophages [81], it is possible that systemic LIF
administration reduces inflammation among peripheral leukocytes through is transduction pathway.

Conclusion
Through this study and previously published manuscripts, this lab has demonstrated that LIF treatment
after stroke promotes neuroprotection and recovery
through two distinct mechanisms: Akt-dependent upregulation of antioxidant enzymes [46, 47] and modulation
of the IL-12 p40/IFNγ/IP-10 signaling pathway. Future

studies dictate that these studies need to be replicated in
aged rodents of both sexes, since several groups have
identified sex-specific and age-dependent differences in
stroke pathophysiology, specifically concerning the
post-stroke immune response [82–86].
This laboratory is currently performing studies to determine the neuroprotective efficacy and anti-inflammatory
action of LIF in aged (18 month) male and female rats
after stroke. Preliminary results show that LIF exhibits potent anti-inflammatory signaling in the splenocytes of aged
female rats after stroke. This study on aged animals also
includes the use of flow cytometry to determine whether
ischemic conditions alter the expression of LIFR on subpopulations of immune cells after stroke [87]. Although
there are antagonists available for LIFR [88], it is very difficult to isolate the specific effects of LIFR after exogenous
LIF treatment, since LIFR is also crucial for the signaling
of other IL-6 family cytokines [89–91]. Therefore,
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Fig. 13 The immunomodulatory effects of LIF. a Release of IL-12 from monocytes/macrophages activates the IL-12/IFNγ/IP-10 axis, b which
promotes chemotaxis to the ischemic brain and increases neuroinflammation. By preventing the increase in splenic IP-10, LIF attenuates the
migration of immune cells from the spleen to the ischemic brain

Davis et al. Journal of Neuroinflammation (2018) 15:288

examining expression of LIFR among leukocyte populations might provide further insight into how LIF promotes
anti-inflammatory signaling in splenocytes and peripheral
blood leukocyte after stroke.
Nevertheless, these data demonstrate the need for
new therapeutics that target the peripheral immune
response in addition to directly promoting neuroprotection after stroke.
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